Your browser is no longer supported. Please, upgrade your browser.
ORGO Organogenesis Holdings Inc. daily Stock Chart
Organogenesis Holdings Inc.
Index- P/E- EPS (ttm)-1.09 Insider Own91.84% Shs Outstand91.66M Perf Week-20.54%
Market Cap563.71M Forward P/E- EPS next Y-0.36 Insider Trans- Shs Float6.81M Perf Month-16.78%
Income-80.40M PEG- EPS next Q-0.12 Inst Own1.20% Short Float5.43% Perf Quarter-21.25%
Sales250.60M P/S2.25 EPS this Y-96.80% Inst Trans3.58% Short Ratio6.05 Perf Half Y-88.82%
Book/sh0.36 P/B17.08 EPS next Y18.20% ROA- Target Price10.67 Perf Year-38.75%
Cash/sh0.33 P/C18.42 EPS next 5Y- ROE- 52W Range6.08 - 310.90 Perf YTD-39.41%
Dividend- P/FCF- EPS past 5Y- ROI-50.60% 52W High-98.02% Beta-
Dividend %- Quick Ratio1.30 Sales past 5Y- Gross Margin93.20% 52W Low1.15% ATR0.42
Employees700 Current Ratio1.60 Sales Q/Q60.80% Oper. Margin- RSI (14)28.60 Volatility9.47% 6.17%
OptionableNo Debt/Eq2.70 EPS Q/Q- Profit Margin- Rel Volume0.40 Prev Close6.20
ShortableNo LT Debt/Eq2.63 EarningsAug 09 BMO Payout- Avg Volume61.12K Price6.15
Recom1.30 SMA20-17.12% SMA50-14.67% SMA200-47.76% Volume24,211 Change-0.81%
May-02-19Initiated Credit Suisse Outperform $9
Apr-17-19Initiated Oppenheimer Outperform $11
Apr-11-19Initiated SunTrust Buy $11
Jul-08-19 08:00AM  Organogenesis Announces 2019 Sponsorship of American Podiatric Medical Association Educational Programs and Annual Scientific Meeting GlobeNewswire
Jul-01-19 07:30AM  Organogenesis Joins Russell 2000®, Russell 3000® and Russell Microcap® Indexes GlobeNewswire +5.26%
May-10-19 12:17PM  Organogenesis Holdings Inc. (ORGO) Q1 2019 Earnings Call Transcript Motley Fool
07:08AM  Organogenesis Holdings Inc. Reports First Quarter 2019 Financial Results GlobeNewswire
May-01-19 08:30AM  Organogenesis Receives Innovative Technology Contract from Vizient GlobeNewswire
Apr-30-19 08:30AM  Latest Wound Care Research from Organogenesis Highlighted at SAWC Spring 2019 GlobeNewswire
Apr-02-19 07:30AM  Organogenesis Holdings Inc. to Report First Quarter of Fiscal Year 2019 Financial Results on May 10, 2019 GlobeNewswire
Apr-01-19 08:30AM  Organogenesis Compliant With Nasdaq Listing Criteria GlobeNewswire
Mar-18-19 04:05PM  Organogenesis Holdings Inc. Reports Fourth Quarter and Fiscal Year 2018 Financial Results GlobeNewswire
Mar-14-19 04:05PM  Organogenesis Holdings Inc. Announces New $100 Million Credit Agreement with Silicon Valley Bank and MidCap Financial PR Newswire
Mar-12-19 09:00AM  Organogenesis Holdings Inc. Announces ReNu® Clinical Trial Results at AAOS 2019 Annual Meeting GlobeNewswire
Mar-11-19 07:30AM  Organogenesis Holdings Inc. to Present at Oppenheimers 29th Annual Healthcare Conference GlobeNewswire +38.08%
Mar-04-19 09:00AM  New Study Shows PuraPly® Antimicrobial Positively Impacts Course of Healing Across Variety of Wound Types GlobeNewswire
Feb-25-19 08:00AM  Organogenesis Holdings Inc. to Report Fourth Quarter and Fiscal Year 2018 Financial Results on March 18, 2019 GlobeNewswire
Jan-24-19 10:00AM  Organogenesis to Sponsor Jan. 30 Webinar, Chronic Wounds and Biofilms: Advancing Assessment and Treatment, Featuring Dr. Gregory Schultz GlobeNewswire -8.13%
Jan-07-19 05:54PM  Organogenesis Holdings Inc. Receives Positive Nasdaq Listing Determination PR Newswire
04:15PM  Nasdaq Scheduled Resumption in Organogenesis Holdings Inc. GlobeNewswire
Organogenesis Holdings Inc., a regenerative medicine company, focuses on the development, manufacture, and commercialization of solutions for the advanced wound care, and surgical and sports medicine markets primarily in the United States. The company's advanced wound care products include Apligraf for the treatment of venous leg ulcers and diabetic foot ulcers (DFUs); Dermagraft for treating DFUs; PuraPly AM to address biofilm across a range of wound types; and Affinity and NuShield to address various wound sizes and types. Its surgical and sports medicine products comprise ReNu for in-office joint and tendon applications; NuCel for bony fusion in the spine and extremities; NuShield and Affinity for surgical applications in targeted soft tissue repairs; and PuraPly AM for the surgical treatment of open wounds. The company's pipeline products include TransCyte for the treatment of second- and third-degree burns; PuraForce, a bioengineered porcine collagen surgical matrix for use in soft tissue reinforcement applications; Novachor for the treatment of chronic and acute wounds; Gintuit for the treatment of mucogingival conditions in adults; and PuraPly XT and PuraPly MZ for the treatment of chronic and acute wounds, as well as for surgical treatment of open wounds. It serves hospitals, wound care centers, government facilities, ambulatory service centers, and physician offices. The company sells its products through direct sales representatives and independent agencies. Organogenesis Holdings Inc. was founded in 1985 and is headquartered in Canton, Massachusetts.